Literature DB >> 8532024

Serum immunoreactive-leptin concentrations in normal-weight and obese humans.

R V Considine1, M K Sinha, M L Heiman, A Kriauciunas, T W Stephens, M R Nyce, J P Ohannesian, C C Marco, L J McKee, T L Bauer.   

Abstract

BACKGROUND: Leptin, the product of the ob gene, is a hormone secreted by adipocytes. Animals with mutations in the ob gene are obese and lose weight when given leptin, but little is known about the physiologic actions of leptin in humans.
METHODS: Using a newly developed radioimmunoassay, wer measured serum concentrations of leptin in 136 normal-weight subjects and 139 obese subjects (body-mass index, > or = 27.3 for men and > or = 27.8 for women; the body-mass index was defined as the weight in kilograms divided by the square of the height in meters). The measurements were repeated in seven obese subjects after weight loss and during maintenance of the lower weight. The ob messenger RNA (mRNA) content of adipocytes was determined in 27 normal-weight and 27 obese subjects.
RESULTS: The mean (+/- SD) serum leptin concentrations were 31.3 +/- 24.1 ng per milliliter in the obese subjects and 7.5 +/- 9.3 ng per milliliter in the normal-weight subjects (P < 0.001). There was a strong positive correlation between serum leptin concentrations and the percentage of body fat (r = 0.85, P < 0.001). The ob mRNA content of adipocytes was about twice as high in the obese subjects as in the normal-weight subjects (P < 0.001) and was correlated with the percentage of body fat (r = 0.68, P < 0.001) in the 54 subjects in whom it was measured. In the seven obese subjects studied after weight loss, both serum leptin concentrations and ob mRNA content of adipocytes declined, but these measures increased again during the maintenance of the lower weight.
CONCLUSIONS: Serum leptin concentrations are correlated with the percentage of body fat, suggesting that most obese persons are insensitive to endogenous leptin production.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8532024     DOI: 10.1056/NEJM199602013340503

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  1305 in total

1.  Short-term treatment with estrone oleate in liposomes (Merlin-2) does not affect the expression of the ob gene in Zucker obese rats.

Authors:  C Adán; M M Grasa; C Cabot; M Esteve; R Vilà; R Masanés; J Estruch; J A Fernández-López; X Remesar; M Alemany
Journal:  Mol Cell Biochem       Date:  1999-07       Impact factor: 3.396

Review 2.  Recent advances in the genetics of severe childhood obesity.

Authors:  I S Farooqi; S O'Rahilly
Journal:  Arch Dis Child       Date:  2000-07       Impact factor: 3.791

3.  Leptin and puberty.

Authors:  P E Clayton; J A Trueman
Journal:  Arch Dis Child       Date:  2000-07       Impact factor: 3.791

4.  Effect of one morning meal and a bolus of dexamethasone on 24-hour variation of serum leptin levels in humans.

Authors:  B Laferrère; S K Fried; T Osborne; F X Pi-Sunyer
Journal:  Obes Res       Date:  2000-10

Review 5.  Promising new approaches to the management of obesity.

Authors:  I L Mertens; L F Van Gaal
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

6.  More on adrenal activity in the metabolic syndrome.

Authors:  Michael L Tuck; Dalila B Corry
Journal:  Curr Hypertens Rep       Date:  2002-04       Impact factor: 5.369

7.  Effects of sibutramine in non-dieting obese women.

Authors:  A Gokcel; Y Gumurdulu; H Karakose; B M Karademir; R Anarat
Journal:  J Endocrinol Invest       Date:  2002-02       Impact factor: 4.256

Review 8.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 9.  Complex interactions in complex traits: obesity and asthma.

Authors:  K G Tantisira; S T Weiss
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

10.  Leptin: a novel therapeutic role in lipodystrophy.

Authors:  D B Savage; S O'Rahilly
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.